» Articles » PMID: 38524629

Prediction of Immunotherapy Response in Idiopathic Membranous Nephropathy Using Deep Learning-pathological and Clinical Factors

Overview
Specialty Endocrinology
Date 2024 Mar 25
PMID 38524629
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Owing to individual heterogeneity, patients with idiopathic membranous nephropathy (IMN) exhibit varying sensitivities to immunotherapy. This study aimed to establish and validate a model incorporating pathological and clinical features using deep learning training to evaluate the response of patients with IMN to immunosuppressive therapy.

Methods: The 291 patients were randomly categorized into training (n = 219) and validation (n = 72) cohorts. Patch-level convolutional neural network training in a weakly supervised manner was utilized to analyze whole-slide histopathological features. We developed a machine-learning model to assess the predictive value of pathological signatures compared to clinical factors. The performance levels of the models were evaluated using the area under the receiver operating characteristic curve (AUC) on the training and validation tests, and the prediction accuracies of the models for immunotherapy response were compared.

Results: Multivariate analysis indicated that diabetes and smoking were independent risk factors affecting the response to immunotherapy in IMN patients. The model integrating pathologic features had a favorable predictive value for determining the response to immunotherapy in IMN patients, with AUCs of 0.85 and 0.77 when employed in the training and test cohorts, respectively. However, when incorporating clinical features into the model, the predictive efficacy diminishes, as evidenced by lower AUC values of 0.75 and 0.62 on the training and testing cohorts, respectively.

Conclusions: The model incorporating pathological signatures demonstrated a superior predictive ability for determining the response to immunosuppressive therapy in IMN patients compared to the integration of clinical factors.

References
1.
Liang Q, Li H, Xie X, Qu F, Li X, Chen J . The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy. Ren Fail. 2017; 39(1):512-518. PMC: 6014322. DOI: 10.1080/0886022X.2017.1325371. View

2.
Orth S . Effects of smoking on systemic and intrarenal hemodynamics: influence on renal function. J Am Soc Nephrol. 2003; 15 Suppl 1:S58-63. DOI: 10.1097/01.asn.0000093461.36097.d5. View

3.
Debiec H, Ronco P . Immunopathogenesis of membranous nephropathy: an update. Semin Immunopathol. 2014; 36(4):381-97. DOI: 10.1007/s00281-014-0423-y. View

4.
Couser W . Primary Membranous Nephropathy. Clin J Am Soc Nephrol. 2017; 12(6):983-997. PMC: 5460716. DOI: 10.2215/CJN.11761116. View

5.
Rojas-Rivera J, Fervenza F, Ortiz A . Recent Clinical Trials Insights into the Treatment of Primary Membranous Nephropathy. Drugs. 2021; 82(2):109-132. PMC: 8844164. DOI: 10.1007/s40265-021-01656-1. View